JARDIANCE® (Empagliflozin)
The content on this website is in relation to adult patients
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
If managing CV risk and preventing mortality is your goal for your T2D patients with CVD, CHOOSE JARDIANCE
What's New
Simple dosing for your patients with T2D1
Efficacy
CV death was an exploratory endpoint in the EMPA-REG OUTCOME® study in patients with T2D and established cardiovascular disease.
Safety Profile
Click & Learn
NICE NG28 Guideline Type 2 diabetes in adults: management
Stay informed
Sign up to receive electronic communications from Boehringer Ingelheim, about BI's products, services and events.
Helpful resources supporting you every step of the way
Digital patient booklet
NICE guidance updates (NG28)
JARDIANCE Initiation & Management guide for T2D, CHF and CKD
Abbreviations
ARR: absolute risk reduction; CV: cardiovascular; CVD: cardiovascular disease; CKD: chronic kidney failure; eGFR: estimated glomerular filtration rate; HbA1c: haemoglobin A1c; LVEF: left ventricular ejection fraction; NICE: National Institute for Health and Care Excellence; RRR: relative risk reduction; SGLT2is: sodium-glucose co-transporter-2 inhibitors; T2D: type 2 diabetes mellitus.
References
- JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
- Zinman B, et al. N Engl J Med. 2015;373:2117–2128.
- National Institute for Health and Care Excellence (NICE) Guideline [NG28] Type 2 diabetes in adults: management (revised 2022). https://www.nice.org.uk/guidance/ng28 (accessed October 2022).
- Nowakowska M, et al. BMC Med. 2019;17:145.
- Sarafidis P, et al. Nephrol Dial Transplant. 2019;34;208-230.
- Inzucchi SE, et al. Circulation. 2018;138:1904–1907.
- Fitchett D, et al. J Am Coll Cardiol. 2018;71:364–367.
- Verma S, et al. Diabetes. 2020:69(Suppl 1):28-OR.
- Claggett B, et al. Circulation. 2018;138:1599–1601.
PC-GB-108847 V2
March 2024